There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

As well, Novo Nordisk® has earlier announced a successful outcome of a human trial of 3,533 people with CKD and type 2 diabetes using injected semaglutide. The study 'demonstrated a statistically ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

For the 12% of adults in the U.S. now taking a weight-loss medication that targets the GLP-1 and/or GIP hormones to restrict ...

This study estimates that approximately one-third of U.S. adults without diabetes who were eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic ...

Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...

Eli Lilly reported total tirzepatide sales that rocketed 272% year over year to $11 billion during the first nine months of ...